In summary, the present study demonstrated that the recombinant humanized IgG1 antibody alleviates hyperlipidemia and in vitro study shows its lipid-lowering activity might be through reinforcement of RCT in an FcRn-ERK1/2-PPARα dependent manner. Here, FCGRT is linked to hyperlipidemia.